uMotif has appointed three new executive leaders: Gary Parrott as Chief Financial Officer, Kristine Klinger as Chief Delivery Officer, and Elaine Maynard as Vice President Marketing.
Worldwide Clinical Trials added Tom Zhang, PhD to the company's early phase clinical trials leadership team as Chief Scientist, Large Molecule Bioanalysis.
Suvoda LLC announced the hiring of Jill Platko, PhD as Vice President of Scientific Services.
Dr. Vince Clinical Research announced the addition of Michelle Neaderhiser as the Director of Study Management, and Chris Hardage as the Director of Clinical Trial Services.
THREAD announced the executive appointment of Kim Boericke as Chief Delivery Officer.
Xenia Kovacs has joined HeartcoR Solutions as associate director of project management.
WCG announced it has appointed its first Chief Product Officer, Rahul Bafna.
AARDEX Group and BIOCORP announced they have been recruited by Trials@Home to take part in a Phase IV study called RADIAL.
Clinical trial sponsors have relied on Calyx’s Interactive Response Technology (IRT) System in clinical trials supporting the approval of over 150 orphan drug indications, as designated by global regulators.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.